Spike S1 (B.1.617.2, Delta Variant) Avi-His-Tag (SARS-CoV-2) Recombinant

• Background:

  The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) . As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.

• Description:

  Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV2 variant B.1.617.2, also known as variant Delta, originally discovered in India, and contains mutations T19R, G142D, R158G, L452R, T478K, D614G and P681R as well as deletion E156-F157. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis) . The protein was affinity purified.

• UniProt:

  P0DTC2

• Tag:

  C-terminal Avi-His-tag

• Purity:

  ≥ 90%

• Format:

  Aqueous buffer solution

• Shipping Conditions:

  -80°C

• Storage Conditions:

  At least 6 months at -80°C.

• Calculated Molecular Weight:

  78 kDa + glycans

• Formulation:

  8 mM phosphate, pH 7.4,110 mM NaCl, 2.2 mM KCl, 20% glycerol

• Glycosylation:

  This protein runs at a higher MW by SDS-PAGE due to glycosylation.